Clinical Trials
Distinguished Clinical Programmer Swaruparani Kolla Surpasses Decade of Outstanding Contributions in Clinical Trials
Principal Clinical SAS Programmer Swaruparani Kolla recently marked her 11-year anniversary of critical contributions in clinical trial data highlighted by years of increasing responsibilities in some of the world’s largest CROs and pharmaceutical companies. She leads a team of...
News
The Role of CBT in Treating Eating Disorders in San Francisco
Eating disorders have become a pressing concern in today's society, impacting people from all walks of life.
San Francisco, like many other urban areas, faces its share of challenges when it comes to these disorders. The fast-paced lifestyle, media influence,...
IT & Data Management
Digital Backdrop In Pharma & The Change It Is Experiencing
The enlarged significance of digital innovation has prominently transformed how pharma goes on to function. A worldwide surge in traffic when it comes to health and medicine websites has only moved forward. The fact is that larger numbers of...
IT & Data Management
GenAI & Its Prominence To Speed-Up Pharmaceuticals To Market
The fact is that Generative AI- GenAI is revolutionizing the life sciences sector, and one is just at the surface of it.
It is worth noting that, on average, it takes almost seven years to come up with a new...
IT & Data Management
GenAI & Its Current Scenario In The World of Pharmaceuticals
According to a recent survey from the Pistoia Alliance, AI and machine learning- ML are going to be the top technology investments when it comes to 60% of life sciences companies in the next two years. 1
With this growing...
Drug Research
Calls For Generic Drugs Safety Tests Resisted By The FDA
Apparently, when a grocery store goes on to steeply discount rotting cuts of meat or produce, would one buy them? May be not. If we go by the same logic, if a pharmacy went ahead and sold medications that...
News
7 Indicators Pointing Towards Life Sciences Growth In 2024
The year 2023 was indeed quite a challenging year for the life sciences industry, which was marked by a chilly biotech financing environment, uncertainty when it came to legislative and policy changes, as well as an unpredictable macroeconomic outlook....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read